Sen. Chuck Schumer sent a letter to acting FDA Commissioner Kyle Diamantas urging the agency to use its enforcement authorities to remove unlawful products from the market, with a focus on Chinese-made vapes flooding U.S. stores.

The letter, sent September 29, comes as the FDA faces mounting pressure to act on the thousands of vaping products still sold without authorization. While Schumer's focus is on vapes, the enforcement mechanism he's calling for—market removal of products without premarket tobacco product applications (PMTAs) or marketing denial orders—applies equally to nicotine pouches.

What This Means for Pouches

The FDA has the same legal authority to pull unauthorized pouches as it does vapes. Hundreds of pouch SKUs remain on shelves despite lacking FDA authorization, particularly flavored products and high-strength options that never received marketing granted orders.

If the FDA responds to Schumer's push with aggressive enforcement, pouch retailers could see the same warning letters and seizure actions that have hit vape shops. The agency has issued pouch-related warning letters before, but enforcement has been inconsistent.

The Enforcement Gap

The FDA's current approach relies heavily on voluntary compliance and warning letters. Actual product seizures and injunctions remain rare, even for products the agency has explicitly denied or that never applied for authorization.

Schumer's letter doesn't specify which enforcement tools the FDA should deploy, but the agency's options include:

• Warning letters to retailers and distributors
• Import refusals at the border
• Seizure of products already in commerce
• Injunctions against manufacturers and distributors

The acting commissioner role adds uncertainty. Diamantas is serving temporarily, and major enforcement shifts typically require political backing and resource allocation that interim leadership may not pursue.

Timeline and Next Steps

Schumer's letter doesn't set a deadline for FDA action. The agency rarely responds publicly to congressional requests, and any enforcement ramp-up would likely unfold over months, not weeks.

For pouch brands, the risk isn't new—it's been present since the September 2020 PMTA deadline. What's changed is the political pressure. If the FDA does move on vapes, the same scrutiny could extend to any nicotine product category with widespread unauthorized sales.

Retailers carrying pouches without FDA authorization should watch for warning letter patterns. The FDA typically signals enforcement priorities through clusters of letters before escalating to seizures.

SOURCES:
Tobacco Reporter